Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,551 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ulcerative Clear all

Conditions: Venous Ulcer
Interventions: XCell cellulose wound dressing, Impregnated gauze dressing; Device
Lead sponsor: Xylos Corporation; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 3
States / cities: Boston, Massachusetts • The Bronx, New York • Philadelphia, Pennsylvania

Conditions: Venous Ulcers
Interventions: Blood Draw; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 377 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Marginal Ulcer, Chronic Ulcer Disease, Persistent Ulcer Disease, Recurrent Ulcer Disease, Late Morbidity After Gastric Bypass
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Fresno, California

Conditions: Chronic Granulomatous Disease, Inflammatory Gastrointestinal Disease, Inflammatory Skin Disease, Inflammatory Lung Disease
Interventions: XELJANZ (tofacitinib); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pressure Ulcer
Interventions: BlastX with negative pressure therapy; Device
Lead sponsor: SerenaGroup, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Kittanning, Pennsylvania

Conditions: Ulcerative Colitis
Interventions: A plant based high fiber diet that mimics fasting ("FMD") plus advanced therapy, Advanced therapy only without dietary intervention; Other · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Ulcerative Colitis
Interventions: ALTB-268; Biological
Lead sponsor: AltruBio Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 23
States / cities: San Diego, California • Littleton, Colorado • Miami, Florida + 20 more

Conditions: Diabetic Foot Ulcers, Venous Stasis Ulcer, Pressure Ulcer, Chronic Non Healing Wound, Surgical Wound Dehiscence
Interventions: Cellular and tissue based products; Biological
Lead sponsor: U.S. Wound Registry; Other
Eligibility: Not listed
Enrollment: 50,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: The Woodlands, Texas

Conditions: n Ulcer, Scleroderma, Systemic
Interventions: Ambrisentan; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Ulcerative Colitis
Interventions: Hydroxocobalamin with Butyrate, Placebo with Butyrate; Drug
Lead sponsor: Joshua Korzenik; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Mobility Limitation
Interventions: Lightweight wheelchair, Skin Protection Cushion; Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 60 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Ulcerative Colitis
Interventions: RAVANS, RAVANS-sham; Device
Lead sponsor: Cala Health, Inc.; Industry
Eligibility: 10 Years to 39 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: Gastric Ulcer, Duodenal Ulcer
Interventions: Esomeprazole 40 mg, Esomeprazole 20 mg, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 2,426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 55
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 52 more

Conditions: Ulcerative Colitis
Interventions: Mirikizumab IV, Mirikizumab SC; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: San Francisco, California • Atlanta, Georgia • Indianapolis, Indiana + 3 more

Conditions: Pressure Injury, Venous Ulcer, Necrotizing Soft Tissue Infection, Diabetic Ulcers, Draining Wound
Interventions: MicroMatrix® Flex, MicroMatrix® UBM Particulate, Cytal® Wound Matrix 2-Layer; Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 22 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Lake Success, New York

Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease, Malignant Solid Neoplasm, Multiple Sclerosis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis
Interventions: Biospecimen Collection, Cabozantinib, Fluoropyrimidine, Ipilimumab, Nivolumab, Platinum Compound, Platinum Doublet; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 51
States / cities: Birmingham, Alabama • Palo Alto, California • Sacramento, California + 37 more

Conditions: Chronic Wound, Burn Wound, Diabetic Foot Ulcers, Pressure Ulcers, Venous Leg Ulcers, Chronic, Wound
Interventions: Epiceram Skin Barrier Function, Vaseline Petroleum Jelly; Device · Biological
Lead sponsor: Sashwati Roy; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2034
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
Interventions: GORE® VIAFORT Vascular Stent; Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 24
States / cities: Stanford, California • Darien, Connecticut • New Haven, Connecticut + 20 more

Conditions: Decubitus Ulcer, Pressure Ulcer
Interventions: Thermal imaging; Device
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Chronic Pressure Ulcers
Interventions: PuraPly® Antimicrobial Wound Matrix, SOC for Pressure Ulcers; Device · Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Lake Success, New York • Mineola, New York

Conditions: Helicobacter Pylori Infection, Gastric Ulcer, Nausea, Abdominal Pain, Weight Loss, Stomach Ulcer, Loss of Appetite, Bloating
Interventions: Newly Diagnosed; Other
Lead sponsor: DiaSorin Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 11
States / cities: Mesa, Arizona • Mission Hills, California • Oxnard, California + 8 more

Conditions: Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease, Depression
Interventions: Primary and Secondary Coping Enhancement Training, Supportive Non-directive Therapy; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 12 Years to 17 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Colitis, Ulcerative
Interventions: GSK2982772, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 6
States / cities: Moreno Valley, California • San Diego, California • Marrero, Louisiana + 3 more

Conditions: Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis
Interventions: Joint visits; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 16 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Nashville, Tennessee

Search by objective public record fields.

Effectiveness of XCell on Autolytic Debridement of Venous Ulcers

Clinical Implications of Genetic Variations of Venous Stasis Ulceration

Chronic Marginal Ulcers After Gastric Bypass

Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications

Evaluating Blast-X® in Combination With Negative Pressure Wound Therapy

Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis

Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

Cellular and Tissue Based Therapy Registry

A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).

Hydroxocobalamin Approach for Reducing of Calprotectin With Butyrate for Ulcerative Colitis Remission

Wheeled Mobility for Preventing Pressure Ulcers

Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Study in Ulcerative Colitis

Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

MicroMatrix® Flex in Tunneling Wounds

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Wound Healing Endpoint and Recurrence

The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study

Thermal Imaging to Identify Distinct Temperature Patterns in Various Stages of Pressure Ulcers

PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.

Helicobacter Pylori Sample Collection Protocol Pre Therapy Subjects

Understanding and Treating Neuropsychiatric Symptoms of Pediatric Physical Illness

GSK2982772 Study in Subjects With Ulcerative Colitis

Transition of Inflammatory Bowel Disease (IBD) Patients From Pediatric to Adult Gastroenterologist (GI)